CHARGED ALPHA
Stock Analysis
PFE Healthcare Latest YouTube: Q1 2026

Pfizer Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Library coverage

Episodes tracked
3
Episodes linked
2
Latest video
Q1 2026
Podcast available
Yes
Current price
$26.21
+0.08 (+0.31%)
Trailing / Forward P/E
20.01x
Forward: 9.26x
Market cap / Volume
Volume:
Revenue / Earnings Growth
5.4%
Earnings: -10.1%
Margins
31.6% op
Gross: 74.8% · Net: 11.8%
Balance sheet
1.25x current
Debt / Equity: 71.6
52-week range / Beta
$23.11 - $28.75
Beta: 0.29
Analyst target
$29.19
Upside: 11.4%
Cash / shareholder return
8.29% FCF yield
Dividend yield: 6.57%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees:
Price to book: 1.66x
Return on equity: 8.3%
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Price chart

Market context for PFE

Competitive view

PFE vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Pfizer Inc. latest YouTube video thumbnail YouTube
Pfizer Inc.
PFE
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
PFE
$149.38B
Pfizer Inc.
ISRG
$145.58B
Intuitive Surgical
JNJ
$579.83B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
PFE
20.0x
Pfizer Inc.
ISRG
50.0x
Intuitive Surgical
JNJ
27.9x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
PFE
9.3x
Pfizer Inc.
ISRG
34.9x
Intuitive Surgical
JNJ
18.9x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
PFE
5.4%
Pfizer Inc.
ISRG
23.0%
Intuitive Surgical
JNJ
9.9%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
PFE
-10.1%
Pfizer Inc.
ISRG
18.8%
Intuitive Surgical
JNJ
-52.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
PFE
31.6%
Pfizer Inc.
ISRG
30.9%
Intuitive Surgical
JNJ
27.4%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
PFE
74.8%
Pfizer Inc.
ISRG
66.3%
Intuitive Surgical
JNJ
68.0%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
PFE
11.8%
Pfizer Inc.
ISRG
28.2%
Intuitive Surgical
JNJ
21.8%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
PFE
8.3%
Pfizer Inc.
ISRG
17.2%
Intuitive Surgical
JNJ
26.4%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
PFE
8.3%
Pfizer Inc.
ISRG
1.6%
Intuitive Surgical
JNJ
2.2%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
PFE
71.60x
Pfizer Inc.
ISRG
Intuitive Surgical
JNJ
67.73x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
PFE
1.25x
Pfizer Inc.
ISRG
4.61x
Intuitive Surgical
JNJ
1.02x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
PFE
0.29
Pfizer Inc.
ISRG
1.45
Intuitive Surgical
JNJ
0.26
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
PFE
6.6%
Pfizer Inc.
ISRG
Intuitive Surgical
JNJ
2.2%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
PFE
11.4%
Pfizer Inc.
ISRG
37.5%
Intuitive Surgical
JNJ
5.0%
Johnson & Johnson

Episode timeline

Episode archive for PFE

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
Published youtube podcast complete
PFE Stock: $14.4B Revenue — Q1 2026 Earnings Analysis
Quarterly earnings-analysis entry for Pfizer Inc.. Use the links on the right to open the video or podcast episode.
Q1 2026
Episode pending
Pending link pending
PFE Q1 2026 earnings analysis
Quarterly earnings-analysis entry for Pfizer Inc.. Use the links on the right to open the video or podcast episode.
No verified episode link yet
Q4 2025
Episode live
Published youtube podcast complete
Charged Alpha | Pfizer (PFE) | Q4 2025 Earnings Deep Dive — Ep. 120
Quarterly earnings-analysis entry for Pfizer Inc.. Use the links on the right to open the video or podcast episode.